In last trading session, BioXcel Therapeutics Inc (NASDAQ:BTAI) saw 0.34 million shares changing hands with its beta currently measuring 0.57. Company’s recent per share price level of $2.13 trading at -$0.11 or -5.12% at ring of the bell on the day assigns it a market valuation of $7.01M. That closing price of BTAI’s stock is at a discount of -2227.7% from its 52-week high price of $49.58 and is indicating a premium of 19.25% from its 52-week low price of $1.72. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 16.64 million shares which gives us an average trading volume of 4.69 million if we extend that period to 3-months.

For BioXcel Therapeutics Inc (BTAI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.25. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -5.14 in the current quarter.

BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information

Upright in the red during last session for losing -5.12%, in the last five days BTAI remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $2.13 price level, adding 44.68% to its value on the day. BioXcel Therapeutics Inc’s shares saw a change of -64.40% in year-to-date performance and have moved -36.80% in past 5-day. BioXcel Therapeutics Inc (NASDAQ:BTAI) showed a performance of -24.20% in past 30-days. Number of shares sold short was 0.33 million shares which calculate 0.07 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 1 to the stock, which implies a fall of -113.0% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 1. It follows that stock’s current price would jump 53.05% in reaching the projected high whereas dropping to the targeted low would mean a gain of 53.05% for stock’s current value.

BioXcel Therapeutics Inc (BTAI) estimates and forecasts

This year revenue growth is estimated to rise 106.09% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 718.26k for the same. And 2 analysts are in estimates of company making revenue of 350k in the next quarter. Company posted 376k and 582k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -35.97% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 74.52% while estimates for its earnings growth in next 5 years are of 50.29%.

BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders

Insiders are in possession of 15.38% of company’s total shares while institution are holding 14.06 percent of that, with stock having share float percentage of 16.62%. Investors also watch the number of corporate investors in a company very closely, which is 14.06% institutions for BioXcel Therapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at BTAI for having 0.97 million shares of worth $1.24 million. And as of 2024-06-30, it was holding 3.1438 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 0.44 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.4276 of outstanding shares, having a total worth of $0.56 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 55.39 shares of worth $0.12 million or 1.73% of the total outstanding shares. The later fund manager was in possession of 18.33 shares on Dec 31, 2024 , making its stake of worth around $39049.0 in the company or a holder of 0.57% of company’s stock.